A Preclinical Package to Maximize the Value of Your MASH Candidate
Featured in Frontiers in Immunology:
A Preclinical Package to Maximize the Value of Your MASH Candidate
We are excited to share that a study for which we conducted the preclinical efficacy pharmacology has been published in the journal, Frontiers in Immunology. The paper features the novel MASH drug candidate, “OATD-01,” from our client, Molecure S.A.
▼ Research from our client, Molecure S.A. (Frontiers in Immunology)
This study achieved consistent efficacy and unique mechanistic insights by employing a multi-faceted evaluation that combined several MASH models with different etiologies (STAM™, DIAMOND, CDHFD).
Take Your Drug Discovery to the Next Level
If you face any of the following challenges with your current compound, we are here to help.
Demonstrating the potential of a complex mechanism of action in the optimal model.
Struggling to build a convincing data package for your compound.
Confirming efficacy not only in the liver but also across multiple organs.
As demonstrated in this case study, we specialize in designing complex study protocols and proposing preclinical strategies to maximize the value of your compound.